Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep;25(9):1745-1747.
doi: 10.3201/eid2509.190023.

Delays in Coccidioidomycosis Diagnosis and Associated Healthcare Utilization, Tucson, Arizona, USA

Delays in Coccidioidomycosis Diagnosis and Associated Healthcare Utilization, Tucson, Arizona, USA

Fariba M Donovan et al. Emerg Infect Dis. 2019 Sep.

Abstract

Tucson, Arizona, USA, is a highly coccidioidomycosis-endemic area. We conducted a retrospective review of 815 patients in Tucson over 2.7 years. Of 276 patients with coccidioidomycosis, 246 had a delay in diagnosis; median delay was 23 days. Diagnosis delay was associated with coccidioidomycosis-related costs totaling $589,053 and included extensive antibacterial drug use.

Keywords: Arizona; Tucson; Valley fever; antimicrobial drugs; coccidioidomycosis; delay in diagnosis; fungi; healthcare cost.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative distribution for time to diagnosis of coccidioidomycosis for 4 disease categories among patients in Tucson, Arizona, USA, January 1, 2015–September 18, 2017. Time points related to patients with very extended delay period (909 days in acute pulmonary disease, 928 days in pulmonary nodule, and 3,315 days in disseminated disease) are not shown in the graph. Timeline truncated for readability.
Figure 2
Figure 2
Coccidioidomycosis costs by disease category for 264 case-patients in Tucson, Arizona, USA, January 1, 2015–September 18, 2017. Costs are shown in 2 columns for each category: the left column for diagnosis at initial presentation and the right column for delayed diagnosis. Each symbol represents 1 case. Numbers in parentheses indicate the number of cases in each category. Cost axis truncated for readability.

References

    1. Nguyen C, Barker BM, Hoover S, Nix DE, Ampel NM, Frelinger JA, et al. Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis. Clin Microbiol Rev. 2013;26:505–25. 10.1128/CMR.00005-13 - DOI - PMC - PubMed
    1. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63:e112–46. 10.1093/cid/ciw360 - DOI - PubMed
    1. Valdivia L, Nix D, Wright M, Lindberg E, Fagan T, Lieberman D, et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis. 2006;12:958–62. 10.3201/eid1206.060028 - DOI - PMC - PubMed
    1. Kim MM, Blair JE, Carey EJ, Wu Q, Smilack JD. Coccidioidal pneumonia, Phoenix, Arizona, USA, 2000-2004. Emerg Infect Dis. 2009;15:397–401. 10.3201/eid1563.081007 - DOI - PMC - PubMed
    1. Chang DC, Anderson S, Wannemuehler K, Engelthaler DM, Erhart L, Sunenshine RH, et al. Testing for coccidioidomycosis among patients with community-acquired pneumonia. Emerg Infect Dis. 2008;14:1053–9. 10.3201/eid1407.070832 - DOI - PMC - PubMed

Publication types